ME00930B - Progesterone for the prevention of preterm birth - Google Patents

Progesterone for the prevention of preterm birth

Info

Publication number
ME00930B
ME00930B MEP-2009-265A MEP26509A ME00930B ME 00930 B ME00930 B ME 00930B ME P26509 A MEP26509 A ME P26509A ME 00930 B ME00930 B ME 00930B
Authority
ME
Montenegro
Prior art keywords
progesterone
drug according
cervix
pregnancy
administration
Prior art date
Application number
MEP-2009-265A
Other languages
French (fr)
Unknown language (me)
Inventor
George Creasy
Brien Jr John M O'
Emily A Defranco
Kenneth N Muse
Original Assignee
Columbia Laboratories Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00930(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Laboratories Bermuda Ltd filed Critical Columbia Laboratories Bermuda Ltd
Publication of ME00930B publication Critical patent/ME00930B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Postupak  za  lečenje   ili  prevencjju  spontanog  prevremenog   porođaja   kod  trudnica  i poboljšavanje neonatalnog morbiditeta i smrtnosti. Postupak obuhvata davanje trudnicama efikasne  količine  progesterna  dovoljne da produži  trudnoću  minimiziranjem skraćivanja  ili  otvaranja  njihovog  grlića. Tretman  i profilaksa progesteronom  trudnica koje  imaju  simpotme   kratkog   grlića  je  klinički  dokazano   da  povećava   neonatalno zdravlje.A procedure for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The procedure involves giving pregnant women an effective amount of progesterone sufficient to prolong their pregnancy by minimizing the shortening or opening of their cervix. Treatment and prophylaxis with progesterone of pregnant women with symptoms of short cervix has been clinically proven to increase neonatal health.

Claims (29)

1. Lek koji sadrži progesteron za upotrebu u lečenju i sprečavanju početka prevremenih trudova i naknadnog porođaja kod trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm, gde je progesteron prisutan u količini koja je dovoljna da minimizira skraćenje grlića.1. A medicament containing progesterone for use in treating and preventing the onset of preterm labor and subsequent labor in pregnant women with a short cervix of about 1.0 cm to about 3.5 cm, wherein progesterone is present in an amount sufficient to minimize shortening of the cervix. 2. Lek prema zahtevu l, koji je u obliku vaginalnog gela, vaginalne supozitorije, vaginalne kreme ili vaginalnog čvrstog doznog oblika.2. The drug according to claim 1, which is in the form of a vaginal gel, vaginal suppository, vaginal cream or vaginal solid dosage form. 3. Lek prema zahtevu l, koji je formulisan za davanje intramuskulamo, oralno, rektalno, subkutanozno, vaginalno, intradermalno, lokalno, intranazalno, intraperitonealno, intraartikulamo, intraventrikulamo, intratekalno, intravaginalno ili intravenskim putem.3. The drug according to claim 1, which is formulated for administration intramuscularly, orally, rectally, subcutaneously, vaginally, intradermally, topically, intranasally, intraperitoneally, intraarticularly, intraventricularly, intrathecally, intravaginally or intravenously. 4. Lek prema bilo kom od prethodnih zahteva, u kojima je progesteron prirodni progesteron ili metabolit progesterona.4. A medicament according to any one of the preceding claims, wherein the progesterone is naturally occurring progesterone or a metabolite of progesterone. 5. Lek prema bilo kom od prethodnih zahteva, u kome progesteron obuhvata sintetički progesteron izabran od 17-alfa-hidroksiprogesteron kaproata, medroksiprogesteron acetata, noretindron, noretindron acetata, noretindron etantata, dezogestrela, levonorgestrel, linesterol, etinodiol diacetata, norgestrela, norgestimata, noretinodrela, gestodena, drospirenona, trimegestrona, levodesogestrela, gestodina, nesterona, etonogestrela i derivata 19-nor-testosterona.5. The drug according to any of the preceding claims, in which the progesterone comprises a synthetic progesterone selected from 17-alpha-hydroxyprogesterone caproate, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethindrone ethanate, desogestrel, levonorgestrel, linesterol, ethynodiol diacetate, norgestrel, norgestimate, noretinodrel , gestodene, drospirenone, trimegestrone, levodesogestrel, gestodyne, nesterone, etonogestrel and 19-nor-testosterone derivatives. 6. Lek prema bilo kom od prethodnih zahteva za dnevno davanje.6. Medicine according to any of the previous requirements for daily administration. 7. Lek prema bilo kom od prethodnih zahteva, za davanje od oko 18. do 22. nedelje trudnoće do oko 37. nedelje trudnoće.7. A drug according to any of the preceding claims, for administration from about 18 to 22 weeks of pregnancy to about 37 weeks of pregnancy. 8. Lek prema zahtevu 6, za davanje u toku perioda od oko 14 do 19 nedelja.8. The drug according to claim 6, for administration during a period of about 14 to 19 weeks. 9. Lek prema zahtevu 6, za davanje od oko 16. nedelje trudnoće do oko 37. nedelje trudnoće.9. The drug according to claim 6, for administration from about the 16th week of pregnancy to about the 37th week of pregnancy. 10. Lek prema zahtevu 6, za davanje u toku perioda od oko 21 nedelje.10. The drug according to claim 6, to be administered over a period of about 21 weeks. 11. Lek prema zahtevu 6, za davanje od vremena pozitivnog testa trudnoće do oko 37. nedelje trudnoće.11. The drug according to claim 6, to be administered from the time of a positive pregnancy test until about the 37th week of pregnancy. 12. Lek prema zahtevu 6, za davanje od oko 2. do 4. nedelje trudnoće.12. The drug according to claim 6, for administration from about the 2nd to the 4th week of pregnancy. 13. Lek prema zahtevu 6 za davanje u toku 33 do 35 nedelja.13. Medicine according to claim 6 for administration during 33 to 35 weeks. 14. Lek prema zahtevu 6 za davanje u zavisnosti od vremena trudnoće na početku tretmana i dana porođaja.14. Medicine according to claim 6 for administration depending on the time of pregnancy at the beginning of the treatment and the day of delivery. 15. Lek prema bilo kom od prethodnih zahteva, koji je formulisan za davanje od oko 45 mg do oko 800 mg progesterona.15. A medicament according to any one of the preceding claims, which is formulated to administer from about 45 mg to about 800 mg of progesterone. 16. Lek prema bilo kom od prethodnih zahteva, koji je u obliku ili sadrži sistem za davanje leka koji sadrži progesteron, vodorastvoran i umetženi polimer polikarboksilne kiseline koji bubri u vodi i bar jedno pomoćno sredstvo.16. A drug according to any of the preceding claims, which is in the form of or contains a drug delivery system containing progesterone, a water-soluble and intercalated water-swellable polycarboxylic acid polymer, and at least one excipient. 17. Lek prema bilo kom od prethodnih zahteva, gde grlić trudnice ima dužinu veću od oko 1.0 cm.17. A drug according to any of the preceding claims, wherein the cervix of the pregnant woman has a length greater than about 1.0 cm. 18. Lek prema bilo kom od prethodnih zatheva, gde grlić trudnice ima dužinu od oko 1.0 cm do oko 3.0 cm.18. The drug according to any one of the preceding claims, wherein the cervix of the pregnant woman has a length of about 1.0 cm to about 3.0 cm. 19. Lek prema bilo kom od prethodnih zahteva, gde grlić trudnice ima dužinu manju ili jednaku oko 3.0 cm.19. A drug according to any of the preceding claims, wherein the cervix of the pregnant woman has a length less than or equal to about 3.0 cm. 20. Lek prema bilo kom od prethodnih zahteva, gde progesteron obuhvata i prirodni progesteron i 17-alfa-hidroksiprogesteron.20. A drug according to any one of the preceding claims, wherein the progesterone comprises both natural progesterone and 17-alpha-hydroxyprogesterone. 21. Lek prema bilo kom od prethodnih zahteva, koji je formulisan za davanje doze od oko 90 mg progesterona i gde je progesteron prirodni progesteron.21. A medicament according to any one of the preceding claims, which is formulated to deliver a dose of about 90 mg of progesterone and wherein the progesterone is naturally occurring progesterone. 22. Lek prema bilo kom od prethodnih zahteva, koji je za upotrebu u poboljšanju neonatalnog morbiditeta i smrtnosti kod prevremene novorođenčadi, očekivane ili naknadno rođene, od trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm.22. A medicament according to any one of the preceding claims, for use in improving neonatal morbidity and mortality in premature infants, expected or postterm, of pregnant women with a short cervix of about 1.0 cm to about 3.5 cm. 23. Lek prema bilo kom od prethodnih zahteva, koji je za davanje u kombinaciji sa jednim ili više jedinjenja za lečenje ili profilaksu prevremenog porođaja.23. A drug according to any one of the preceding claims, which is for administration in combination with one or more compounds for the treatment or prophylaxis of preterm labor. 24. Lek prema bilo kom od zahteva l do 22, koji je za davanje u kombinaciji sa kliničkim postupkom za lečenje ili profilasku prevremenog porođaja.24. The drug according to any one of claims 1 to 22, which is to be administered in combination with a clinical procedure for the treatment or prophylaxis of preterm labor. 25. Upotreba progesterona u proizvodnji leka za lečenje ili sprečavanje početka trudova i naknadnog prevremenog porođaja kod trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm, gde je progesteron korišćen u količini koje je dovoljna da minimizira skraćenje grlića.25. Use of progesterone in the manufacture of a medicament for treating or preventing the onset of labor and subsequent premature labor in pregnant women with a short cervix of about 1.0 cm to about 3.5 cm, wherein the progesterone is used in an amount sufficient to minimize shortening of the cervix. 26. Uređaj za davanje leka koji je konstruisan za umetanje u vaginu, koji sadrži lek prema bilo kom od zahteva l do 22.26. A drug delivery device designed to be inserted into the vagina, containing a drug according to any one of claims 1 to 22. 27. Uređaj za davanje prema zahtevu 26, pri čemu je uređaj cervikalni prsten, ili uređaj sadrži cervikalni prsten.27. The delivery device of claim 26, wherein the device is a cervical ring, or the device comprises a cervical ring. 28. Postupak za lečenje ili sprečavanje početka prevremenih trudova i naknadnog prevremenog porođaja kod trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm, koji se sastoji od davanja ženama progesterona u količini dovoljnoj da smanji skraćenje grlića.28. A procedure for treating or preventing the onset of preterm labor and subsequent preterm birth in pregnant women with a short cervix of about 1.0 cm to about 3.5 cm, which consists of giving the woman progesterone in an amount sufficient to reduce the shortening of the cervix. 29. Postupak poboljšavanja neonatalnog morbiditeta i smrtnosti kod prevremeno rođene odojčadi koji se sastoji od davanja trudnicama sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm progesterona u količni dovoljnoj da smanji ili odloži dalje skraćenje grlića ili produži trudnoću.29. A method of improving neonatal morbidity and mortality in premature infants comprising administering to pregnant women with a short cervix of about 1.0 cm to about 3.5 cm progesterone in a quantity sufficient to reduce or delay further shortening of the cervix or prolong the pregnancy.
MEP-2009-265A 2007-02-06 2008-02-05 Progesterone for the prevention of preterm birth ME00930B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88848007P 2007-02-06 2007-02-06
US97366707P 2007-09-19 2007-09-19
PCT/GB2008/000397 WO2008096122A2 (en) 2007-02-06 2008-02-05 Progesterone for the prevention of preterm birth

Publications (1)

Publication Number Publication Date
ME00930B true ME00930B (en) 2012-03-20

Family

ID=39301249

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-265A ME00930B (en) 2007-02-06 2008-02-05 Progesterone for the prevention of preterm birth

Country Status (23)

Country Link
US (2) US8828981B2 (en)
EP (1) EP2117554B1 (en)
JP (2) JP5580601B2 (en)
KR (1) KR101546101B1 (en)
AR (1) AR065179A1 (en)
AU (1) AU2008212724A1 (en)
BR (1) BRPI0807203A2 (en)
CA (1) CA2677354C (en)
CL (1) CL2008000375A1 (en)
CO (1) CO6220941A2 (en)
CR (1) CR10985A (en)
ES (1) ES2596803T3 (en)
GE (1) GEP20135727B (en)
IL (1) IL200272A (en)
MA (1) MA31200B1 (en)
ME (1) ME00930B (en)
MX (1) MX2009008409A (en)
MY (1) MY184866A (en)
NZ (1) NZ579114A (en)
PE (1) PE20081738A1 (en)
RU (1) RU2524617C2 (en)
TW (1) TWI471135B (en)
WO (1) WO2008096122A2 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344693T3 (en) 2002-08-13 2010-09-03 N-Dia, Inc. DEVICES AND PROCEDURES FOR DETECTING AMNIOTIC LIQUID IN VAGINAL SECRETIONS.
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
PT2249757T (en) 2008-02-04 2017-11-15 Ferring Bv Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
CA2738605A1 (en) 2008-09-24 2010-04-01 Luke Anthony O'neill Composition and method for treatment of preterm labor
GB0905964D0 (en) * 2009-04-06 2009-05-20 King S College London Marker
US20110152840A1 (en) * 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
CA2789238C (en) * 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
WO2012058463A2 (en) * 2010-10-27 2012-05-03 Dignity Health Trimegestone (tmg) for treatment of preterm birth
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
ES2885523T3 (en) 2011-11-23 2021-12-14 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102012009057A1 (en) * 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotational pessary made from a polymer comprises an active substance against premature births
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2941644B1 (en) 2013-01-02 2019-09-11 Qiagen Sciences, LLC Methods for predicting time-to-delivery in pregnant women
MX2016014281A (en) 2014-05-22 2017-02-22 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies.
PL2982352T3 (en) * 2014-06-28 2019-01-31 Laboratorios Andrómaco S.A. Cervical pessary containing progesterone for prolonged, sustained and continuous release, used to prevent premature birth
MX2016013693A (en) 2014-07-29 2017-10-31 Therapeuticsmd Inc Transdermal cream.
KR101726488B1 (en) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 Composition for the treatment of pregnancy-related diseases comprising the extracellular vesicles derived from Bacillus spp.
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
JP2018522854A (en) 2015-06-22 2018-08-16 リポカイン インコーポレーテッド Oral compositions containing 17-hydroxyprogesterone esters and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017040243A1 (en) * 2015-08-28 2017-03-09 Kypha, Inc. Methods for predicting flare and improving treatment of patients
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20190282588A1 (en) * 2016-05-16 2019-09-19 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
JP2018140172A (en) * 2017-02-28 2018-09-13 株式会社Ｎｔｔドコモ Data collection apparatus and data collection method
US11207509B2 (en) 2017-06-15 2021-12-28 Wiesman Holdings, LLC Method and device for delivery of a solution into a body orifice
RU2657772C1 (en) * 2017-07-06 2018-06-15 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области Method of preventing gestational complications in pregnant women with epilepsy
US20190038637A1 (en) * 2017-08-05 2019-02-07 Eric Marchewitz Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
KR20200094742A (en) * 2017-10-30 2020-08-07 카르멘틱스 피티이. 리미티드 Preterm biomarkers
RU2692932C2 (en) * 2017-11-07 2019-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) BIOCATALYST FOR PRODUCING 11α-ACETOXYPROGESTERONE
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
JP7301326B2 (en) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 Neonatal to childhood-onset cerebrovascular disease or method for detecting carriers thereof
WO2020191297A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Methods of treatment of spontaneous preterm birth
JP2022527411A (en) * 2019-03-29 2022-06-01 マーテル，ブリジット Segmented EVA vaginal ring
KR102157438B1 (en) * 2019-04-16 2020-09-21 고려대학교 산학협력단 Method and Kit for diagnosing preterm birth
CA3152099A1 (en) * 2019-09-23 2021-04-01 Liang Liang Methods of treatments to prolong gestation and complications of menstruation or gestation
US11439588B2 (en) 2019-10-12 2022-09-13 National Research Institute For Family Planning Vaginal sustained-release drug delivery system for luteal support, method for preparation and use thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
KR102482468B1 (en) * 2020-08-11 2022-12-28 연세대학교 산학협력단 Methods for providing information about preterm birth and device using the same
US20220072008A1 (en) * 2020-09-08 2022-03-10 Cedars-Sinai Medical Center Method of using progesterone receptor agonists for the treatment of covid-19
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery
WO2022173786A1 (en) * 2021-02-10 2022-08-18 Mirvie, Inc. Methods and systems for conducting pregnancy-related clinical trials
KR102823321B1 (en) * 2022-01-17 2025-06-19 연세대학교 산학협력단 Method for providing information of the cervix and device using the same
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
DE4229820C2 (en) 1992-09-07 1998-12-03 Jenapharm Gmbh Progestogen-based pharmaceutical preparation
US5830848A (en) 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US5948762A (en) 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
UA57703C2 (en) 1995-03-14 2003-07-15 Шерінг Актієнгезеллшафт Method for stimulation and inhibition of cervical dilatation and extensibility
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5744463A (en) * 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DE69819748T2 (en) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. MEDICINES FOR TREATING DYSMENORRHEA AND PREVIOUS BLIES
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US5941888A (en) * 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
PE20010640A1 (en) 1999-06-21 2001-06-06 Columbia Lab Bermuda Ltd USE OF EXOGENOUS ESTROGEN OR A SUBSTANCE THAT CAUSES THE RELEASE OF THE ESTROGEN FOR THE PROGRAMMING OF OVULATION
US6375970B1 (en) * 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
PL367961A1 (en) 2001-08-31 2005-03-07 Schering Oy Drug delivery system
FR2832065B1 (en) * 2001-11-13 2004-11-05 Besins Int Belgique PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF
FR2842108B1 (en) 2002-07-09 2008-05-02 Effik COMPOUNDS BASED ON HORMONE AND NITROGEN MONOXIDE AND THEIR USE IN OBSTETRICS AND GYNECOLOGY
CA2512989A1 (en) 2003-02-06 2004-08-26 Adeza Biomedical Corporation Screening and treatment methods for prevention of preterm delivery
EP2392332A1 (en) 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
ES2381495T3 (en) 2005-05-26 2012-05-28 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods for manufacturing and using them
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Also Published As

Publication number Publication date
US7884093B2 (en) 2011-02-08
IL200272A0 (en) 2010-04-29
IL200272A (en) 2014-02-27
WO2008096122A2 (en) 2008-08-14
RU2524617C2 (en) 2014-07-27
JP5580601B2 (en) 2014-08-27
CR10985A (en) 2009-10-23
CA2677354C (en) 2015-07-07
CO6220941A2 (en) 2010-11-19
AU2008212724A1 (en) 2008-08-14
RU2009133315A (en) 2011-03-20
TW200902030A (en) 2009-01-16
KR101546101B1 (en) 2015-08-20
BRPI0807203A2 (en) 2014-07-22
KR20090123875A (en) 2009-12-02
CL2008000375A1 (en) 2008-05-30
JP2010518058A (en) 2010-05-27
MA31200B1 (en) 2010-02-01
US20080188829A1 (en) 2008-08-07
US20090264395A1 (en) 2009-10-22
HK1136975A1 (en) 2010-07-16
TWI471135B (en) 2015-02-01
CA2677354A1 (en) 2008-08-14
US8828981B2 (en) 2014-09-09
ES2596803T3 (en) 2017-01-12
MX2009008409A (en) 2009-09-16
JP2014058529A (en) 2014-04-03
MY184866A (en) 2021-04-28
GEP20135727B (en) 2013-01-25
PE20081738A1 (en) 2008-11-20
WO2008096122A3 (en) 2009-02-26
EP2117554B1 (en) 2016-07-13
NZ579114A (en) 2012-07-27
EP2117554A2 (en) 2009-11-18
AR065179A1 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
ME00930B (en) Progesterone for the prevention of preterm birth
USRE39861E1 (en) Methods of extended use oral contraception
CA2789238C (en) Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
TWI549681B (en) Monolithic intravaginal ring containing progestogen and method of making and using same
KR20060126671A (en) Prolonged use combinations including estrogen and progestin
HUT51899A (en) Contraception system and process
US20050101579A1 (en) Endometriosis treatment protocol
ZA200404249B (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Hammad et al. An overview of contraception in women with obesity
Meckstroth et al. Prostaglandins for first-trimester termination
US20030018018A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
Pongsatha et al. Intravaginal misoprostol for pregnancy termination
Bjørge et al. Early pregnancy termination with mifepristone and misoprostol in Norway
Segal et al. Breast-feeding and contraception
Depypere et al. A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause
CN101583364A (en) Pharmaceutical preparation for the alleviation of endometriosis
McDaniel et al. Return of menstruation and fertility in Thai women after contraceptive injections
Amrutha Comparative study of efficacy and safety of Mifepristone and Foley’s catheter in induction of labour
Żyła et al. Progestins-a review of clinical application in gynecology
Sandstrøm et al. Interruption of early pregnancy with mifepristone in combination with gemeprost
Mandlekar et al. 36.1 TERMINATION OF EARLY PREGNANCY BY MEDICAL METHODS
Corriere Jr et al. Bacteriuria in young women Effect of estrogen, progestogen, and estrogen-progestogen combination
Ma et al. POSTCOITAL BLEEDING 60
Caret et al. The antifertility effectiveness of low doses of ethinyl oestradiol
Dhont Non-contraceptive benefits of oral contraceptives